Janagliflozin

Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1) . Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus[1][2].

Product Specifications

CAS Number

[1800115-22-3]

UNSPSC

12352005

Target

SGLT

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Metabolic Disease

Smiles

[H][C@](C1)(C2)[C@@]1([H])C[C@H]2OC3=CC=C(C=C3)CC4=CC([C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)=CC=C4Cl

Molecular Formula

C25H29ClO6

Molecular Weight

460.95

References & Citations

[1]Song L, et al. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor. Clin Pharmacokinet. 2023 Mar;62 (3) :505-518.|[2]Zhao H, et al. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. Eur J Pharm Sci. 2022 Dec 1;179:106298.